Premium
P4‐350: Long‐term instability of glycemic control is associated with poorer cognitive function
Author(s) -
Beeri Michal Schnaider,
RavonaSpringer Ramit,
Moshier Erin,
Schmeidler James,
Godbold James,
Preiss Rachel,
Hofmann Hadas,
Koifman Keren,
Heymann Anthony
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2013.08.131
Subject(s) - medicine , glycemic , body mass index , type 2 diabetes , diabetes mellitus , dementia , neuropsychology , cognition , physical therapy , pediatrics , gerontology , psychiatry , endocrinology , disease
patients who completed the Souvenir II study. In the OLE study, all patients received Souvenaid daily. Safety parameters included adverse events, vital signs and laboratory parameters. Compliance was assessed using a daily diary and by studying (nutritional) biomarkers of compliance. The memory domain score resulting from a Neuropsychological Test Battery, the primary endpoint of the Souvenir II study, was included as an exploratory outcome in the OLE study. Study staff and patients remained blinded to patient’s initial study group allocation throughout the 48 weeks. Results: The Souvenir II study demonstrated a significant effect on memory during 24 weeks intervention (Scheltens et al. J Nutr Health Aging 2011; 15(S1), S13). Of the 238 patients (91.9%) who completed this study, 198 patients (83.2%) entered the OLE study. This extension study was completed by 183 patients (92.4%). The study showed that 48-week use of Souvenaid was safe, with a high compliance (>90%). The study additionally indicated that memory performance continued to improve in patients receiving Souvenaid up to 48 weeks. Conclusions: The use of Souvenaid for 48 weeks was safe and well-tolerated in patients with mild AD. Following the significantly improved memory performance over 24 weeks in the double-blind randomised controlled Souvenir II study, t he OLE study indicated that memory continued to improve in patients receiving Souvenaid up to 48 weeks.